Compare ARMOUR Residential REIT, Inc. (ARR) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs Biogen Inc — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.67 (market cap $2.07B), while Biogen Inc trades at $204.1 (market cap $30.13B). The key difference: Biogen Inc is far larger — about 14.6× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays a 17.28% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| ARR | BIIB | |
|---|---|---|
Market Cap | $2.07B | $30.13B |
Sector | Financials | Health |
52-Week High | $19.12 | $216.63 |
52-Week Low | $14.05 | $128.93 |
Dividend Yield | 17.28% | — |
Enterprise Value | — | $37.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARR trades at $16.67, up 0.79% today, with a neutral technical signal and mixed earnings history. The stock shows strong profitability with a net income margin of 97.43% and a low P/E of 3.78, but revenue volatility and high investing cash outflows pose concerns. Recent dividends of $0.24 per share highlight income appeal, while analyst consensus is predominantly hold.
Outlook is cautious due to inconsistent EPS performance and significant cash flow swings, though valuation metrics suggest potential undervaluation. Risks include earnings misses and macroeconomic sensitivity, but the high dividend yield and low P/B ratio offer value for income-focused investors amid neutral market sentiment.
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
